



✚ Pharmathen

2023

API PRODUCT
CATALOGUE



Company Profile

We are one of the leading complex drug delivery and formulation developers, using our key in-house technologies to support improved patient compliance. We service a broad partner network of 250+ customers in 90+ countries throughout Europe, North America, South America, Middle East, Asia, Australasia and Southern Africa.

Our portfolio consists of over 100 products, and today we are working on one of the most extensive and advanced pipelines of Long Acting Injectables (LAI) and other complex injectables, Sustained Release Oral Solid and Ophthalmic formulations, both Preserved and Preservative free, produced in our US-FDA and EU-approved manufacturing facilities.

We have fully validated to commercial scale multiple LAI in each of the three major LAI technology platforms (Microspheres, Nanosuspensions and Nano-Gels), and have registered these products with regulatory authorities in multiple countries globally. These platforms now support the enrichment of our pipeline with the addition of Long-Acting Therapeutic Technologies (LATT) which will target enhanced patient compliance for existing drug delivery therapies and methods, and support product Life Cycle Management (LCM) opportunities. In addition, through the utilization of these key technologies, we're offering B2B partnering solutions either for new drug candidates or your own LCM LATT candidates.

We proudly employ more than 1,300 people from over 22 different nationalities across 9 locations. Through our everyday activities and drug delivery advancements we remain committed to our vision "to make a difference in people's lives".

API product list 2023



PRODUCT	INDICATION	STATUS
APREPITANT	Prevention of acute and delayed chemotherapy- induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting	EU DMF approved US DMF No.032203
ARIPIRAZOLE	Treatment of Schizophrenia	EU DMF approved
ARIPIRAZOLE LAUROXIL	Maintenance treatment of Schizophrenia in adult patients stabilized with oral aripiprazole	Under development
BRINZOLAMIDE	Ocular hypertension / Open angle Glaucoma	EU DMF approved US DMF No.034167
CHOLECALCIFEROL CONCENTRATE (Powder Form)	Prevention and treatment of vitamin D deficiency	EU DMF approved
CLOPIDOGREL BESYLATE	Acute Coronary Syndrome	EU DMF approved
DIMETHYL FUMARATE	Immunomodulator	US DMF No.030938 EU DMF submitted
FEBUXOSTAT	Chronic management of Hyperuricemia	EU DMF approved
IBANDRONATE	Treatment and Prevention of Postmenopausal Osteoporosis	EU DMF approved
LINEZOLID FORM I	Infection treatment	EU DMF approved
NUSINERSEN	Treatment of spinal muscular atrophy	Under development
PALIPERIDONE	Treatment of Schizophrenia	EU DMF available US DMF No.31062
PALIPERIDONE PALMITATE	Treatment of Schizophrenia	Under development
PREGABALIN	Management of neuropathic pain	EU DMF approved JDMF submitted
ROPINIROLE HCL	Parkinson's Treatment	EU DMF approved
TAPENTADOL	Centrally acting opioid analgesic	EU DMF submitted
TOLTERODINE	Treatment of Overactive bladder	CEP valid
VALGANCICLOVIR	Treatment of Cytomegalovirus (CMV) Retinitis	EU DMF approved
VILDAGLIPTIN	Antidiabetic	EU DMF approved
VORICONAZOLE	Treatment of Invasive Aspergillosis fungal infection	EU DMF approved



www.pharmathen.com

Disclaimer

This catalogue may contain information on worldwide products and services, some of which are not available in every region/country. A reference to a product or service in this catalogue does not imply that such product or service will be available in your region/country. Please consult Pharmathen for any information concerning the products and services currently available in your region / country.

Furthermore, the information provided in this catalogue, including any reference to any product, is for informational purposes only and does not constitute an offer for sale or should not be construed as representing an offer to sell such product. You should not construe anything in this catalogue as a promotion or advertisement for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence.

The present catalogue only relates to 2023 and replaces any previous version."